MyFinsight
Home
Blog
About
Aktis Oncology, Inc. (AKTS)
Aktis Oncology, Inc. (AKTS)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$21,849K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from maturities of mark...
Accrued expenses and other curre...
Depreciation and amortization
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
Net loss
Deferred revenue
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
Net loss
-24,144
-18,325
Depreciation and amortization
879
652
Stock-based compensation
3,222
3,022
Net amortization of premiums and accretion of discounts on investments in marketable securities
-1,033
-529
Prepaid expenses and other current assets
1,619
828
Interest receivable
144
1,105
Operating lease right-of-use assets
599
191
Other assets
111
1,877
Accounts payable
866
-65
Accrued expenses and other current liabilities
4,632
-1,824
Operating lease liabilities
-350
-327
Deferred revenue
-3,384
-3,227
Net cash used in operating activities
-20,587
-24,242
Purchases of marketable securities
300,446
0
Proceeds from maturities of marketable securities
33,000
22,395
Purchases of property and equipment
1,262
1,854
Net cash (used in) provided by investing activities
-268,708
20,541
Proceeds from initial public offering, net of underwriter discounts and commissions paid during the period
0
339,780
Payment of offering costs
0
2,263
Proceeds from exercise of common stock options
156
30
Net cash provided by (used in) financing activities
156
337,547
Net increase in cash, cash equivalents and restricted cash equivalents
-289,139
333,846
Cash, cash equivalents and restricted cash equivalents at beginning of period
372,779
38,933
Cash, cash equivalents and restricted cash equivalents at end of period
83,640
372,779
Cash and cash equivalents
82,491
-
Long-term restricted cash equivalents
1,149
-
Total cash, cash equivalents and restricted cash equivalents
83,640
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from exercise of
common stock options
$156K
Net cash provided by
(used in) financing...
$156K
Net increase in
cash, cash...
-$289,139K
Canceled cashflow
$156K
Proceeds from maturities
of marketable...
$33,000K
Accrued expenses and
other current...
$4,632K
Stock-based compensation
$3,222K
Depreciation and
amortization
$879K
Accounts payable
$866K
Operating lease
right-of-use assets
$599K
Net cash (used in)
provided by investing...
-$268,708K
Net cash used in
operating activities
-$20,587K
Canceled cashflow
$33,000K
Canceled cashflow
$10,198K
Purchases of marketable
securities
$300,446K
Net loss
-$24,144K
Purchases of property and
equipment
$1,262K
Deferred revenue
-$3,384K
Prepaid expenses and
other current assets
$1,619K
Net amortization of
premiums and accretion of...
-$1,033K
Operating lease
liabilities
-$350K
Interest receivable
$144K
Other assets
$111K
Buy us a coffee